Donidalorsen sodium - Generic Drug Details
What are the generic drug sources for donidalorsen sodium and what is the scope of freedom to operate?
Donidalorsen sodium
is the generic ingredient in one branded drug marketed by Ionis Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for donidalorsen sodium
| International Patents: | 316 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | donidalorsen sodium at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for donidalorsen sodium
Generic Entry Date for donidalorsen sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for donidalorsen sodium
US Patents and Regulatory Information for donidalorsen sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for donidalorsen sodium
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015252917 | ⤷ Start Trial | |
| Australia | 2019284028 | ⤷ Start Trial | |
| Brazil | 112016022855 | ⤷ Start Trial | |
| Canada | 2943705 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for donidalorsen sodium
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3137091 | C20265016 | Finland | ⤷ Start Trial | |
| 3524680 | 28/2025 | Austria | ⤷ Start Trial | PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307 |
| 3137091 | 2026C/732 | Belgium | ⤷ Start Trial | PRODUCT NAME: DONIDALORSEN; AUTHORISATION NUMBER AND DATE: EU/1/25/2001 20260120 |
| 3524680 | 301341 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
